Lyell Immunopharma (LYEL) Accumulated Depreciation & Amortization: 2020-2024
- Lyell Immunopharma's Accumulated Depreciation & Amortization rose 36.85% to $70.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $169.2 million, marking a year-over-year increase of 63.27%. This contributed to the annual value of $19.6 million for FY2024, which is 3.06% down from last year.
- As of Q4 2024, Lyell Immunopharma's Accumulated Depreciation & Amortization stood at $70.7 million, which was up 36.85% from $51.6 million recorded in Q4 2023.
- Over the past 5 years, Lyell Immunopharma's Accumulated Depreciation & Amortization peaked at $70.7 million during Q4 2024, and registered a low of $5.1 million during Q4 2020.
- Its 3-year average for Accumulated Depreciation & Amortization is $51.6 million, with a median of $51.6 million in 2023.
- Data for Lyell Immunopharma's Accumulated Depreciation & Amortization shows a peak YoY surged of 184.35% (in 2021) over the last 5 years.
- Lyell Immunopharma's Accumulated Depreciation & Amortization (Quarterly) stood at $5.1 million in 2020, then surged by 184.35% to $14.5 million in 2021, then soared by 123.14% to $32.4 million in 2022, then skyrocketed by 59.48% to $51.6 million in 2023, then surged by 36.85% to $70.7 million in 2024.
- Its Accumulated Depreciation & Amortization was $70.7 million in Q4 2024, compared to $51.6 million in Q4 2023 and $32.4 million in Q4 2022.
